Head-To-Head Contrast: Synergy CHC (NASDAQ:SNYR) & Haleon (NYSE:HLN)

Haleon (NYSE:HLN) and Synergy CHC (NASDAQ:SNYR) are both consumer staples companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Institutional and Insider Ownership

6.7% of Haleon shares are held by institutional investors. 32.9% of Synergy CHC shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Haleon has a beta of 0.12, meaning that its share price is 88% less volatile than the S&P 500. Comparatively, Synergy CHC has a beta of -0.14, meaning that its share price is 114% less volatile than the S&P 500.

Profitability

This table compares Haleon and Synergy CHC’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Haleon	N/A	N/A	N/A
Synergy CHC	-60.02%	N/A	-30.30%

Analyst Ratings

This is a breakdown of current ratings for Haleon and Synergy CHC, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haleon	2	4	3	2	2.45
Synergy CHC	1	1	2	0	2.25

Synergy CHC has a consensus price target of $6.25, suggesting a potential upside of 3,934.86%. Given Synergy CHC’s higher probable upside, analysts plainly believe Synergy CHC is more favorable than Haleon.

Earnings and Valuation

This table compares Haleon and Synergy CHC”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haleon	$14.54 billion	2.90	$2.20 billion	$0.39	24.59
Synergy CHC	$30.38 million	0.08	-$12.34 million	($1.40)	-0.11

Haleon has higher revenue and earnings than Synergy CHC. Synergy CHC is trading at a lower price-to-earnings ratio than Haleon, indicating that it is currently the more affordable of the two stocks.

Summary

Haleon beats Synergy CHC on 12 of the 14 factors compared between the two stocks.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

About Synergy CHC

Synergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME.